Calton & Associates, Inc. Insmed Inc Transaction History

Calton & Associates, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$23.42 - $31.74 $187,196 - $253,697	7,993 New	7,993 $247,000
Q2 2022 Jul 12, 2022	SELL	$17.07 - $25.71 $167,303 - $251,983	-9,801 Closed	0 $0
Q1 2022 Apr 12, 2022	BUY	$20.42 - $28.13 $27,179 - $37,441	1,331 Added 15.71%	9,801 $230,000
Q4 2021 Jan 13, 2022	SELL	$25.89 - $33.45 $4,427 - $5,719	-171 Reduced 1.98%	8,470 $230,000
Q3 2021 Nov 05, 2021	SELL	$22.46 - $29.47 $1,482 - $1,945	-66 Reduced 0.76%	8,641 $237,000
Q2 2021 Aug 11, 2021	SELL	$24.17 - $36.01 $6,791 - $10,118	-281 Reduced 3.13%	8,707 $248,000
Q1 2021 May 03, 2021	BUY	$32.28 - $44.3 $52,067 - $71,455	1,613 Added 21.87%	8,988 $306,000
Q4 2020 Jan 25, 2021	SELL	$31.45 - $40.54 $51,200 - $65,999	-1,628 Reduced 18.08%	7,375 $246,000
Q3 2020 Oct 30, 2020	SELL	$26.0 - $34.5 $11,726 - $15,559	-451 Reduced 4.77%	9,003 $289,000
Q2 2020 Aug 10, 2020	BUY	$14.11 - $29.42 $133,395 - $278,136	9,454 New	9,454 $260,000
Q1 2020 Apr 30, 2020	SELL	$13.63 - $33.98 $119,207 - $297,189	-8,746 Closed	0 $0
Q4 2019 Feb 03, 2020	BUY	$16.12 - $24.98 $140,985 - $218,475	8,746 New	8,746 $209,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.